TLDR Targeted cancer therapies often cause serious skin problems that need careful management.
The document discussed the rapid development of targeted therapies in oncology and their associated cutaneous adverse effects. Dermatologists needed to be aware of these skin-related toxicities, which were common and could be severe enough to limit dosage or discontinue therapy. The article emphasized the importance of understanding the mechanisms and recognizing symptoms to manage these toxicities effectively. It specifically reviewed skin-related adverse effects of inhibitors targeting the cell membrane, including epidermal growth factor receptor, KIT, BCR-ABL, angiogenesis, and multikinase inhibitors.
Cited in this study
6 / 6 results
278 citations
,
May 2013 in “Ca” Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.
9 citations
,
May 2013 in “JAMA Dermatology” A woman's hair turned white after taking a cancer drug called dasatinib.
16 citations
,
March 2013 in “JAMA Dermatology” A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.
42 citations
,
April 2012 in “Seminars in Oncology” Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
32 citations
,
January 2012 in “International Journal of Dermatology” Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
30 citations
,
February 2011 in “American Journal of Clinical Dermatology” Cetuximab can cause eyelash growth, which is rare but manageable.
